Rhumbline Advisers increased its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 7.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 26,364 shares of the biopharmaceutical company's stock after purchasing an additional 1,924 shares during the period. Rhumbline Advisers owned approximately 0.12% of Madrigal Pharmaceuticals worth $8,733,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also added to or reduced their stakes in MDGL. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Madrigal Pharmaceuticals during the 4th quarter worth $70,000. Parallel Advisors LLC grew its position in shares of Madrigal Pharmaceuticals by 42.7% during the first quarter. Parallel Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 85 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Madrigal Pharmaceuticals in the 4th quarter worth approximately $141,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Madrigal Pharmaceuticals during the fourth quarter worth $164,000. Finally, Graham Capital Management L.P. bought a new stake in Madrigal Pharmaceuticals in the 4th quarter valued at $203,000. Institutional investors own 98.50% of the company's stock.
Analyst Ratings Changes
Several research firms have weighed in on MDGL. UBS Group raised their price target on Madrigal Pharmaceuticals from $441.00 to $458.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Wall Street Zen upgraded shares of Madrigal Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday, May 5th. Canaccord Genuity Group increased their target price on shares of Madrigal Pharmaceuticals from $394.00 to $420.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Citigroup raised their price target on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Finally, B. Riley restated a "buy" rating and issued a $460.00 price objective (up from $422.00) on shares of Madrigal Pharmaceuticals in a report on Friday, May 2nd. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $420.63.
View Our Latest Research Report on MDGL
Madrigal Pharmaceuticals Stock Down 1.5%
Shares of NASDAQ MDGL traded down $4.51 during midday trading on Thursday, hitting $289.83. 130,502 shares of the company's stock were exchanged, compared to its average volume of 363,348. The firm's fifty day simple moving average is $297.71 and its 200-day simple moving average is $315.02. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. The company has a market cap of $6.44 billion, a PE ratio of -11.56 and a beta of -1.08. Madrigal Pharmaceuticals, Inc. has a twelve month low of $200.63 and a twelve month high of $377.46.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($3.32) EPS for the quarter, beating analysts' consensus estimates of ($3.62) by $0.30. The business had revenue of $137.25 million during the quarter, compared to analysts' expectations of $112.79 million. During the same period in the previous year, the company posted ($7.38) earnings per share. Research analysts predict that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current fiscal year.
About Madrigal Pharmaceuticals
(
Free Report)
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
See Also

Before you consider Madrigal Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Madrigal Pharmaceuticals wasn't on the list.
While Madrigal Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.